SG144146A1 - Adenosine receptor agonists - Google Patents
Adenosine receptor agonistsInfo
- Publication number
- SG144146A1 SG144146A1 SG200804350-7A SG2008043507A SG144146A1 SG 144146 A1 SG144146 A1 SG 144146A1 SG 2008043507 A SG2008043507 A SG 2008043507A SG 144146 A1 SG144146 A1 SG 144146A1
- Authority
- SG
- Singapore
- Prior art keywords
- receptor agonists
- adenosine receptor
- adenosine
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2004/000902 WO2004079329A2 (fr) | 2003-03-07 | 2004-03-05 | Identification de composes therapeutiques |
GB0405012A GB0405012D0 (en) | 2004-03-05 | 2004-03-05 | Therapeutic compounds |
GBGB0405009.2A GB0405009D0 (en) | 2004-03-05 | 2004-03-05 | Analgesics |
GB0412262A GB0412262D0 (en) | 2004-06-02 | 2004-06-02 | Use of compounds for the treatment of pain |
GB0412261A GB0412261D0 (en) | 2004-06-02 | 2004-06-02 | Analgesics |
GB0413627A GB0413627D0 (en) | 2004-06-18 | 2004-06-18 | Analgesics |
GB0419718A GB0419718D0 (en) | 2004-09-06 | 2004-09-06 | Therapeutic compounds |
GB0420063A GB0420063D0 (en) | 2004-09-09 | 2004-09-09 | Therapeutic compounds |
GB0420615A GB0420615D0 (en) | 2004-09-16 | 2004-09-16 | Therapeutic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG144146A1 true SG144146A1 (en) | 2008-07-29 |
Family
ID=34923594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200804350-7A SG144146A1 (en) | 2004-03-05 | 2005-03-04 | Adenosine receptor agonists |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080221060A1 (fr) |
EP (1) | EP1749016A2 (fr) |
JP (1) | JP2007526291A (fr) |
KR (1) | KR20070004792A (fr) |
AU (1) | AU2005218997B2 (fr) |
BR (1) | BRPI0508488A (fr) |
CA (1) | CA2557285A1 (fr) |
EA (2) | EA014425B1 (fr) |
MX (1) | MXPA06010075A (fr) |
NO (1) | NO20064365L (fr) |
SG (1) | SG144146A1 (fr) |
WO (1) | WO2005084653A2 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
JP2007536241A (ja) * | 2004-05-03 | 2007-12-13 | ユニバーシティ オブ バージニア パテント ファウンデーション | 糖尿病性腎症の処置のためのa2aアデノシンレセプターアゴニスト |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
MX2007005525A (es) * | 2004-11-08 | 2007-07-05 | Can Fite Biopharma Ltd | Tratamiento terapeutico de resorcion ose acelerada. |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
CN1947717B (zh) * | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
US20070183995A1 (en) * | 2006-02-09 | 2007-08-09 | Conopco, Inc., D/B/A Unilever | Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same |
WO2007120972A2 (fr) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Procede permettant de traiter l'anemie a hematies falciformes |
ATE549337T1 (de) | 2006-04-21 | 2012-03-15 | Novartis Ag | Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten |
GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
CN101479290A (zh) * | 2006-06-27 | 2009-07-08 | 比奥维特罗姆上市公司 | 新的2′,3′-亚甲基缩醛腺苷前药用作腺苷受体激动剂的前药 |
RU2009102536A (ru) | 2006-06-27 | 2010-08-10 | Биовитрум Аб (Пабл) (Se) | Терапевтические соединения |
AU2007263728A1 (en) * | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Adenosine derivatives for the treatment of pain |
EP1889846A1 (fr) | 2006-07-13 | 2008-02-20 | Novartis AG | Dérivés de purine comme agonistes du recepteur A2a |
EP1903044A1 (fr) | 2006-09-14 | 2008-03-26 | Novartis AG | Derivés de l'adénosine en tant qu' agonistes du récepteur A2A |
WO2009061516A1 (fr) | 2007-11-08 | 2009-05-14 | New York University School Of Medicine | Implants médicaux contenant des agonistes du récepteur de l'adénosine et procédés pour inhiber un relâchement d'implant médical |
US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
WO2009089425A1 (fr) * | 2008-01-09 | 2009-07-16 | Pgxhealth Llc | Traitement intrathécal d'une douleur neuropathique avec des agonistes a2ar |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
WO2010071865A1 (fr) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Compositions pharmaceutiques et procédés de traitement de l'hyperuricémie et des troubles associés |
WO2011004166A1 (fr) * | 2009-07-09 | 2011-01-13 | Cbt Development Limited | Préparation combinée pour une utilisation en tant que médicament |
WO2011032175A1 (fr) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Formulations combinées de tranilast et d'allopurinol et procédés associées à celles-ci |
WO2011069294A1 (fr) * | 2009-12-10 | 2011-06-16 | 中国医学科学院药物研究所 | Dérivés d'adénosine à substitution n6, dérivés d'adénine à substitution n6 et leurs utilisations |
WO2011123518A1 (fr) * | 2010-03-31 | 2011-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Agonistes de récepteur d'adénosine pour le traitement et la prévention de troubles de calcification de capsule vasculaire ou articulaire |
CA2847540C (fr) * | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Derives de pyrrolopyrimidine et de purine |
FR2981650B1 (fr) * | 2011-10-24 | 2013-12-27 | Univ Paris Curie | Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement |
US20160038526A1 (en) * | 2012-08-16 | 2016-02-11 | Thomas Jefferson University | Treatment of prostate cancer |
US20150209379A1 (en) * | 2012-08-16 | 2015-07-30 | Thomas Jefferson University | Treatment of prostate cancer and hematologic neoplasms |
EP2711008A1 (fr) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | N6,N6-dimethyladenosine destiné à être utilisé dans le traitement ou la prévention du cancer du sein primitif et métastatique |
WO2015085497A1 (fr) * | 2013-12-10 | 2015-06-18 | Scinopharm Taiwan, Ltd. | Procédé de préparation de régadénoson |
EP3573996B1 (fr) * | 2017-01-27 | 2022-06-15 | Academia Sinica | Composé à effet analgésique destiné à être utilisé dans la prévention et le traitement de la douleur |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE792155A (fr) * | 1971-12-01 | 1973-05-30 | Takeda Chemical Industries Ltd | Nouveaux derives de l'adenosine et leur procede de production |
JPS4861498A (fr) * | 1971-12-01 | 1973-08-28 | ||
JPS5549594B2 (fr) * | 1972-12-08 | 1980-12-12 | ||
DE2359536C2 (de) * | 1972-12-08 | 1984-08-02 | Takeda Chemical Industries, Ltd., Osaka | 2,6-Diaminonebularinderivate |
JPS5461194A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | Preparation of n22substituted 2*66diaminonebularin |
JPS5461195A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | N2-substituted phenyl-2,6-diaminonebularin |
US4705758A (en) * | 1984-06-19 | 1987-11-10 | Warner-Lambert Company | Adenosine receptor assay and kit |
US5013829A (en) * | 1989-04-26 | 1991-05-07 | University Of Iowa Research Foundation | Stable congener of 2',3'-dideoxyadenosine |
US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
GB0228723D0 (en) * | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
GB0305153D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
WO2005056571A1 (fr) * | 2003-12-05 | 2005-06-23 | Biovitrum Ab | Synthese amelioree d'adenosines substituees en 2 |
GB0328323D0 (en) * | 2003-12-05 | 2004-01-07 | Cambridge Biotechnology Ltd | Synthesis of 2-substituted adenosines |
GB0401292D0 (en) * | 2004-01-21 | 2004-02-25 | Cambridge Biotechnology Ltd | Synthesis of spongosine |
-
2005
- 2005-03-04 EA EA200800538A patent/EA014425B1/ru not_active IP Right Cessation
- 2005-03-04 BR BRPI0508488-1A patent/BRPI0508488A/pt not_active IP Right Cessation
- 2005-03-04 US US10/598,520 patent/US20080221060A1/en not_active Abandoned
- 2005-03-04 CA CA002557285A patent/CA2557285A1/fr not_active Abandoned
- 2005-03-04 AU AU2005218997A patent/AU2005218997B2/en not_active Expired - Fee Related
- 2005-03-04 MX MXPA06010075A patent/MXPA06010075A/es unknown
- 2005-03-04 SG SG200804350-7A patent/SG144146A1/en unknown
- 2005-03-04 EP EP05717878A patent/EP1749016A2/fr not_active Withdrawn
- 2005-03-04 WO PCT/GB2005/000800 patent/WO2005084653A2/fr active Application Filing
- 2005-03-04 KR KR1020067020304A patent/KR20070004792A/ko not_active Application Discontinuation
- 2005-03-04 JP JP2007501345A patent/JP2007526291A/ja active Pending
- 2005-03-04 EA EA200601642A patent/EA011099B1/ru not_active IP Right Cessation
-
2006
- 2006-09-26 NO NO20064365A patent/NO20064365L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA011099B1 (ru) | 2008-12-30 |
AU2005218997B2 (en) | 2012-05-10 |
EA200601642A1 (ru) | 2006-12-29 |
JP2007526291A (ja) | 2007-09-13 |
EA200800538A1 (ru) | 2008-06-30 |
NO20064365L (no) | 2006-11-22 |
EP1749016A2 (fr) | 2007-02-07 |
CA2557285A1 (fr) | 2005-09-15 |
US20080221060A1 (en) | 2008-09-11 |
EA014425B1 (ru) | 2010-12-30 |
WO2005084653A3 (fr) | 2006-05-18 |
BRPI0508488A (pt) | 2007-07-31 |
KR20070004792A (ko) | 2007-01-09 |
MXPA06010075A (es) | 2007-04-10 |
WO2005084653A2 (fr) | 2005-09-15 |
AU2005218997A1 (en) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG144146A1 (en) | Adenosine receptor agonists | |
IN2014CN03629A (fr) | ||
IL178086A0 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
IL177059A0 (en) | Indazole-carboxamide compounds as 5-ht4 receptor agonists | |
SG149831A1 (en) | Benzimidazole derivatives | |
TW200631955A (en) | Non-hygroscopic and powdery amorphous pimecrolimus | |
IL181716A0 (en) | Purine derivatives as a3 and a1 adenosine receptor agonists | |
IL182645A0 (en) | Use of a2a adenosine receptor agonists | |
SG155211A1 (en) | Peptide | |
IN2014CN03762A (fr) | ||
ATE549350T1 (de) | Neuropeptid-2-rezeptor-agonisten | |
ZA200800405B (en) | Pyrisazinone derivatives as thyroid hormone receptor agonists | |
GB0511124D0 (en) | High affinity melan-a t cell receptors | |
EP2017281A4 (fr) | Agonistes du récepteur 9 de type toll | |
IL174056A0 (en) | Novel adenosine a3 receptor agonists | |
HK1110980A1 (en) | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | |
EP1713815A4 (fr) | Agonistes de pth | |
SG144934A1 (en) | C5a receptor antagonists | |
EP1713782A4 (fr) | Agonistes de pth | |
MX2008000874A (es) | Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina. | |
GB0505732D0 (en) | Plate holder | |
EP1636230A4 (fr) | Antagonistes de recepteur d'adenosine a1 | |
IL177721A0 (en) | Adenosine receptor agonists | |
IL198618A0 (en) | Novel amides acting on the adenosine receptors | |
GB0516439D0 (en) | EP2 receptor agonists |